James M. Foran, MD, FRCPC, Mayo Clinic Cancer Center

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.

Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.

The panel of experts comment on the role of transplant in patients with myelodysplastic syndrome.

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.

Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.

The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.

Rami Komrokji, MD, discusses his approach to treatment in patients with myelodysplastic syndrome, while being mindful of recommended guidelines.

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

James Foran, MD; Azra Raza, MD; and Gail Roboz, MD, discuss how mutation status in myelodysplastic syndrome may impact treatment considerations.

Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center & Research Institute, discusses the importance of examining a patient’s complete blood count, nutritional status and bone marrow when considering a diagnosis of myelodysplastic syndrome.

Gail Roboz, MD; Azra Raza, MD; and Amy DeZern, MD, MHS, discuss the clinical considerations and risk assessments inherent to a diagnosis of myelodysplastic syndrome.